secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2023-08-21T23:59:59+00:00
Accession:  0001493152-23-029522
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos receives Nasdaq deficiency notice for stockholders' equity below $2.5M
----------------------------------------------------------------------------

- Stockholders' equity as of June 30, 2023 was approx. $2.106M, below Nasdaq's $2.5M minimum.
- Company has until October 2, 2023 to submit a compliance plan to Nasdaq.
- If plan accepted, Nasdaq may grant extension through February 13, 2024.
- Failure to regain compliance could lead to delisting; no immediate impact on listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223029522/0001493152-23-029522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223029522/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-029522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer